Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s239, 2023. DOI: 10.25251/skin.7.supp.239. Disponível em: https://skin.dermsquared.com/skin/article/view/2361. Acesso em: 20 may. 2025.